10:00 |
0175. |
31P Magnetic
Resonance Spectroscopy study on the effects of stably
silencing the glycerophosphocholine phosphodiesterase GDPD5
in a breast cancer model in vivo
Jannie P. Wijnen1,2, Lu Jiang1,
Tiffany R. Greenwood1, Maria D. Cao3,
Balaji Krishnamachary1, Dennis W.J. Klomp2,
and Kristine Glunde1
1Johns Hopkins University In Vivo Cellular
and Molecular Imaging Center,Russell H. Morgan
Department, Johns Hopkins University School of Medicine,
Baltimore, Maryland, United States, 2Department
of Radiology, University Medical Centre Utrecht,
Utrecht, Netherlands, 3Department
of Circulation and Medical Imaging, Norwegian University
of Science and Technology, Trontheim, Norway
In the present study, we stably silenced
glycerophosphodiester phosphodiesterase domain
containing 5 (GDPD5) using short hairpin RNA (shRNA)
against GDPD5 and investigated the effects of this
stable GDPD5 silencing in a breast tumour xenograft
model with 31P
Magnetic Resonance Spectroscopy (MRS). Stable silencing
of the GDPD5 gene caused an increase in
glycerophosphocholine (GPC) and a decrease in free
choline in the tumour. This can be explained by the
reduction GDPD5 expression in the GDPD5-silenced tumours,
which leads to less degradation of GPC into free choline
and glycerol-3-phosphate as GDPD5 confers GPC-PDE
activity. We also observed an increase in
phosphoethanolamine, which could be caused by
phosphorylation of ethanolamine by choline and/or
ethanolamine kinase as a compensatory mechanism to
maintain high levels of phosphomonoesters in the cells.
|
10:12 |
0176.
|
Treatment with the MEK
inhibitor U0126 induces a decrease in hyperpolarized
pyruvate to lactate conversion in breast but not in prostate
cancer cells
Alessia Lodi1, Sarah M Woods1, and
Sabrina M Ronen1
1University of California San Francisco, San
Francisco, California, United States
To date, response to anti-neoplastic treatment has been
associated with a drop in 13C MRS-detectable
hyperpolarized pyruvate to lactate conversion. Here we
assessed the effect of treatment with the MEK inhibitor
U0126 in prostate and breast cancer cells. Drug action
resulted in a drop in the pyruvate to lactate conversion
in breast cancer cells, but an increase in prostate
cancer cells. This effect is likely mediated by an
increase in intracellular lactate and LDH expression and
activity in both cancer models and a concurrent drop in
MCT1 expression in breast, but not in prostate cancer
cells.
|
10:24 |
0177.
|
Assessment of Glutamine
Metabolism in Mammary Tumor Recurrence Using 13C
MRS
Dania Daye1,2, Suzanne Wehrli3,
George Belka4,5, Anthony Mancuso6,
Chris Sterner4,5, Mitchell Schnall6,
and Lewis Chodosh4,5
1Abramson Family Cancer Research Institute,
Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, Pennsylvania, United States,2Bioengineering
Graduate Group, University of Pennsylvania,
Philadelphia, Pennsylvania, United States, 3Children's
Hospital of Philadelphia, 4Department
of Cancer Biology, Perelman School of Medicine at the
University of Pennsylvania, 5Abramson
Family Cancer Research Institute, Perelman School of
Medicine at the University of Pennsylvania, 6Department
of Radiology, Perelman School of Medicine at the
University of Pennsylvania
Tumor recurrence represents the principal cause of death
from breast cancer. Despite being a critical clinical
problem, little is known about the cellular and
molecular mechanisms underlying tumor recurrence. Our
laboratory has developed an inducible transgenic mouse
model that accurately reproduces key features of the
natural history of human breast cancer progression
including tumor recurrence. Dysregulated metabolism has
been shown to be key feature of tumorigenesis. To date,
very little is know about the association between
changes in metabolism and cancer recurrence. In this
study, we investigate the role of 13C-glutamine as a
potential breast cancer progression marker using MRS.
|
10:36 |
0178.
|
Mining Lipid Signatures in
a Breast Tumor Model by Combining Magnetic Resonance
Spectroscopic Imaging and Mass Spectrometric Imaging
Lu Jiang1, Kamila Chughtai2,
Tiffany Greenwood1, Gert Eijkel2,
Ron Heeren2, and Kristine Glunde1
1JHU ICMIC Program, Russell H. Morgan
Department of Radiology and Radiological Science, Johns
Hopkins Medical Institute, Baltimore, Maryland, United
States, 2FOM-Institute
AMOLF, Netherlands
The intensity of the total choline (tCho) signal in
magnetic resonance spectroscopic imaging (MRSI) of
tumors is spatially heterogeneous. In vivo H1 MRSI with
the spectral resolution to resolve the components of the
tCho signal and its membrane precursors is currently
unavailable. Mass spectrometry imaging (MSI) of
histologic tumor sections is able to detect thousands of
molecules from the tissue surface. We have investigated
the correlations between tCho, lipid metabolites, and
membrane phospholipids in a human breast cancer model by
combining in vivo MRSI with ex vivo MSI, which
identified specific membrane phosphatidylcholine species
that are decreased in high tCho regions.
|
10:48 |
0179. |
Molecular Correlates to in
vivo Hyperpolarized [1-13C] Dehydroascorbate Reduction
Victor Sai1, Kayvan R. Keshari1,
Romelyn Delos Santos1, John Kurhanewicz1,
and David M. Wilson1
1Radiology and Biomedical Imaging, University
of California, San Francisco (UCSF), San Francisco, CA,
United States
In vivo MRSI studies using HP [1-13C] dehydroascorbate (DHA)
in a transgenic model of prostate cancer (TRAMP) show
rapid uptake of DHA and reduction to Vitamin C. We
hypothesized that this is secondary to increased uptake
via GLUT-type transporters and elevated intracellular
glutathione levels. Gene expression analysis
demonstrated elevated GLUT3 but decreased GLUT1
expression. Thioredoxin reductase was also found to be
elevated. Intracellular glutathione levels were
increased in TRAMP tumor relative to normal prostate,
and mercury orange staining for non-protein thiols was
also increased in TRAMP tumor compared to normal
control.
|
11:00 |
0180.
|
Quantitative Biomarkers of
Cancer from Metabolic Activity Decomposition using
Stimulated-Echoes and Hyperpolarized Carbon-13 MR
Christine M Leon1,2, Peder EZ Larson1,
Adam B Kerr3, Robert Bok1, John M
Pauly3, John Kurhanewicz1, and
Daniel B Vigneron1
1Department of Radiology and Biomedical
Imaging, University of California, San Francisco, San
Francisco, CA, United States, 2UC
Berkeley | UCSF Graduate Group in Bioengineering,
University of California, Berkeley and University of
California, San Francisco, San Francisco, CA, United
States,3Department of Electrical Engineering,
Stanford University, Stanford, CA, United States
We propose a new and robust method for quantification of
dynamic data. Using Metabolic Activity Decomposition, we
investigated real-time conversion parameters as
biomarkers of cancer. Ex vivo enzyme experiments
validated the technique, allowing for direct observation
of real-time conversion, which can only be due to the
LDH enzyme. Conventional modeling yields four unknowns
but only two equations, an underdetermined system of
equations. Using Metabolic Activity Decomposition, twice
the amount of information can be obtained from a same
acquisition providing a well-conditioned system.
Moreover, fitting in vivo data with MAD-STEAM yielded K PyrLac values
that robustly distinguished tumor versus normal
(p-value=0.009)
|
11:12 |
0181.
|
Imaging of Prostate Cancer
Metabolic Heterogeneity with CEST and MT MRI
Kejia Cai1, He N Xu2, Anup Singh1,
Mohammad Haris1, Ravinder Reddy1,
and Lin Z Li2
1CMROI, Department of Radiology, University
of Pennsylvania, Philadelphia, PA, United States, 2Department
of Radiology, University of Pennsylvania, Philadelphia,
PA, United States
Here we report the preliminary data on chemical exchange
saturation transfer (CEST) & magnetization transfer (MT)
magnetic resonance imaging (MRI) and redox scanning of
two aggressive human prostate tumor lines (PC-3 and
DU-145) xenografted in athymic nude mice. The results
obtained by these methods appeared to be consistent with
all showing higher level of heterogeneity in DU-145
tumors than in PC-3 tumors at this stage of tumor
progression. MT and CEST MRI method could serve as a
surrogate metabolic imaging biomarkers for redox imaging
of tumor metastatic potential.
|
11:24 |
0182.
|
Quantitative imaging of
tumour glucose uptake using glucoseCEST: comparison with
18F-FDG autoradiography
Simon Walker-Samuel1, Rajiv Ramasawmy1,
Francisco Torrealdea2, Marilena Rega2,
Peter Johnson3, Vineeth Rajkumar3,
Simon Richardson1, Dave Thomas2,
Barbara Pedley3, Mark F. Lythgoe1,
and Xavier Golay2
1Centre for Advanced Biomedical Imaging,
University College London, London, United Kingdom, 2Institute
of Neurology, University College London, United Kingdom, 3Cancer
Institute, University College London, United Kingdom
We have recently developed a technique named glucoseCEST
that enables the accumulation of exogeneously
administered, unlabelled glucose to be detected in
tumours. Here we present a technique that allows
glucoseCEST measurements to be converted to an absolute
glucose concentration. This approach is evaluated in two
colorectal tumour xenograft models (SW1222 and LS174T)
and compared with 18F-FDG autoradiography. Significant
differences in uptake were observed between tumour cell
lines in both FDG and glucose measurements. Median
tumour glucose and FDG concentrations were also
significant correlated. These results suggest that
glucoseCEST and 18F-FDG autoradiogaphy (and therefore
FDG-PET) may provide corresponding information.
|
11:36 |
0183. |
DCE-MRI and ICP-MS
evaluation of biodistribution of contrast agents and
chemotherapeutic agents to gliomas with a new
pharmacological approach in F98 glioma cells implanted
Fischer rats
Jerome Cote1, Luc Tremblay2, David
Fortin3, Fernand Gobeil4, and
Martin Lepage2
1CIMS, Université de Sherbrooke, Sherbrooke,
Quebec, Canada, 2CIMS,
Université de Sherbrooke, Sherbrooke, Québec, Canada, 3Chirurgie,
Université de Sherbrooke, Sherbrooke, Québec, Canada, 4Pharmacologie,
Université de Sherbrooke, Sherbrooke, Québec, Canada
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
with intravenous Gd-DTPA or Gadomer was used to monitor
the selective increase of blood-brain barrier
permeability at the tumor of glioma-bearing rats,
induced by a novel pharmacological approach. Our results
indicate that the biodistribution of both contrast
agents within rat gliomas and surrounding brain tissues
was doubled. This was confirmed by a two-fold increase
(versus vehicle) of concentrations of Gd-DTPA and
Carboplatin in tumor and peripheral tissues measured by
inductively coupled plasma mass spectrometry (ICP-MS).
|
11:48 |
0184. |
Tumor drug resistance and
sodium-diffusion MRI in rat glioma model
Victor D. Schepkin1, Thomas Morgan2,
Fabian Calixto-Bejarano3, Petr L. Gor'kov3,
William Brey3, Chunqi Qian4,
Shannon Gower-Winter5, Manuel Ozambela2,
and Cathy Levenson2
1CIMAR/MRI, NHMFL/FSU, Tallahassee, FL,
United States, 2College
of Medicine, FSU, Tallahassee, FL, United States, 3CIMAR/NMR,
NHMFL/FSU, Tallahassee, FL, United States, 4NINDS,
NIH, Bethesda, MD, United States, 5College
of Medicine, FSU, Tallahassee, United States
During cancer progression, tumors develop mechanisms
permitting them to obstruct chemotherapeutic
interventions. To formulate individualized treatments it
is important to provide a prompt and noninvasive
assessment of tumor resistance. Mitochondria play a
central role in ATP production, apoptosis and are
associated with changes in tumor resistance. We
hypothesize that the energy metabolism shift due to
increased tumor resistance can affect sodium
homeostasis, and MRI has the potential to reflect
changes in tumor resistance. The results demonstrate
that alterations in tumor resistance can be detected
prior to treatment by sodium and diffusion MRI, allowing
individualized adjustments to prevent ineffective
treatments.
|
|